SQZ Biotechnologies Company (SQZB) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SQZ Biotechnologies Company (SQZB) trades at $0.024 with AI Score 47/100 (Grade C). SQZ Biotechnologies Company is a clinical-stage biotechnology firm specializing in cell therapies for cancer, autoimmune, and infectious diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SQZB: SQZB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SQZB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SQZB: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
SQZ Biotechnologies Company (SQZB) Healthcare & Pipeline Overview
SQZ Biotechnologies Company is a clinical-stage biotechnology firm focused on developing cell therapies using its proprietary SQZ platform. Their lead candidate targets HPV16+ solid tumors and is currently in Phase I trials. The company operates in the competitive biotechnology sector, emphasizing novel antigen-presenting cell therapies.
What Is the Investment Thesis for SQZB?
SQZ Biotechnologies Company presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology firms. The primary value driver is the successful development and commercialization of its SQZ platform-derived cell therapies. The ongoing Phase I clinical trials for SQZ-PBMC-HPV and SQZ-AAC-HPV represent key catalysts. Positive data readouts from these trials could significantly increase the company's valuation. However, the company's negative profit margin of -377.9% underscores its reliance on future funding or partnerships. The company's low Beta of 0.33 suggests lower volatility compared to the broader market, but this may also reflect its illiquidity as an OTC stock. Investors should closely monitor clinical trial progress, regulatory milestones, and the company's cash runway.
Based on FMP financials and quantitative analysis
SQZB Key Highlights
SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on cell therapies.
- Lead product candidate SQZ-PBMC-HPV is in Phase I clinical trials for HPV16+ advanced or metastatic solid tumors.
- The company has a small team of 53 employees.
- The company's profit margin is -377.9%.
- The company's gross margin is 46.6%.
Who Are SQZB's Competitors?
SQZB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HXBM Helix BioMedix, Inc. | $1.75 | +0.00% | 50 | |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SQZB's Key Strengths?
Proprietary SQZ platform technology.
- Early-stage clinical pipeline.
- Expertise in cell engineering.
- Focus on personalized cell therapies.
What Are SQZB's Weaknesses?
Clinical-stage company with no approved products.
- High cash burn rate.
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
What Could Drive SQZB Stock Higher?
SQZB catalyst: Data readout from Phase I clinical trial of SQZ-PBMC-HPV as a monotherapy for HPV16+ solid tumors.
- Data readout from Phase I clinical trial of SQZ-PBMC-HPV in combination with immuno-oncology agents for HPV16+ solid tumors.
- Data readout from Phase I clinical trial of SQZ-AAC-HPV as a monotherapy for HPV16+ solid tumors.
- Data readout from Phase I clinical trial of SQZ-AAC-HPV in combination with immuno-oncology agents for HPV16+ solid tumors.
- Advancement of SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers platforms.
What Are the Key Risks for SQZB?
Financial-distress signal — its Altman Z-Score of -21.82 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-87.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for SQZ-PBMC-HPV or SQZ-AAC-HPV.
- Regulatory delays or rejection of cell therapy products.
- Competition from other biotechnology companies developing cell therapies.
- Difficulty in raising capital to fund research and development.
- Intellectual property infringement or challenges to patent protection.
What Are the Growth Opportunities for SQZB?
- Expansion of SQZ-PBMC-HPV Clinical Trials: A significant growth opportunity lies in expanding the Phase I clinical trials for SQZ-PBMC-HPV to include a broader range of HPV16+ solid tumors and combination therapies. Positive results could lead to Phase II trials and eventual commercialization. The market for HPV-related cancer therapies is substantial, with ongoing research and development focused on improving patient outcomes. Success in this area could establish SQZ Biotechnologies as a key player in the field, potentially generating significant revenue streams within the next 3-5 years.
- Advancement of SQZ-AAC-HPV Program: The SQZ-AAC-HPV program, also in Phase I clinical trials, represents another growth avenue. This program targets the same HPV16+ solid tumors but utilizes a different approach. Positive data from these trials could provide additional validation of the SQZ platform and expand the company's pipeline. The timeline for potential commercialization is similar to SQZ-PBMC-HPV, contingent on successful trial outcomes and regulatory approvals. The market opportunity is directly linked to the prevalence and treatment landscape of HPV-related cancers.
- Development of SQZ Activating Antigen Carriers: The SQZ Activating Antigen Carriers platform offers potential for developing cell therapies for other types of cancer and infectious diseases. Expanding this platform into new therapeutic areas could significantly broaden the company's market reach. The timeline for this growth opportunity is longer-term, potentially 5-7 years, as it requires further research and development. The market size will depend on the specific diseases targeted and the competitive landscape in those areas.
- Development of SQZ Tolerizing Antigen Carriers: The SQZ Tolerizing Antigen Carriers platform targets autoimmune diseases. This represents a significant growth opportunity, as the market for autoimmune disease therapies is large and growing. Success in this area could diversify the company's pipeline and reduce its reliance on oncology. The timeline for this growth opportunity is also longer-term, similar to the Activating Antigen Carriers platform, due to the complexities of autoimmune disease research and development.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of SQZ Biotechnologies' cell therapies. These partnerships could provide access to funding, expertise, and distribution channels. The timeline for this growth opportunity is variable, depending on the specific partnerships pursued. The potential impact on revenue and market share could be substantial, depending on the terms of the agreements.
What Are SQZB's Competitive Advantages?
- Proprietary SQZ platform technology.
- Early-stage clinical pipeline.
- Expertise in cell engineering.
- Intellectual property protection (patents).
What Does SQZB Do?
SQZ Biotechnologies Company, founded in 2013 and headquartered in Watertown, Massachusetts, is a clinical-stage biotechnology company dedicated to creating innovative cell therapies. The company's core technology, the SQZ platform, enables the engineering of a patient's own cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Their lead product candidate, SQZ-PBMC-HPV, is derived from the SQZ Antigen Presenting Cells platform and is currently in a Phase I clinical trial. This trial evaluates the therapy's effectiveness both as a standalone treatment and in combination with immuno-oncology agents for HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancers. In addition to SQZ-PBMC-HPV, the company is also developing SQZ-AAC-HPV, another candidate in Phase I clinical trials targeting HPV16+ advanced or metastatic solid tumors, both as a monotherapy and in combination regimens. SQZ Biotechnologies is also advancing other platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to expand its therapeutic reach. The company's focus is on leveraging its unique cell engineering capabilities to develop personalized therapies that can address significant unmet medical needs. With a team of 53 employees, SQZ Biotechnologies is committed to translating its innovative science into effective treatments for patients facing serious diseases.
What Products and Services Does SQZB Offer?
- Develops cell therapies for cancer.
- Creates therapies for autoimmune diseases.
- Engineers cell therapies for infectious diseases.
- Utilizes the SQZ platform to modify patient cells.
- Conducts Phase I clinical trials for SQZ-PBMC-HPV.
- Conducts Phase I clinical trials for SQZ-AAC-HPV.
- Develops SQZ Activating Antigen Carriers.
- Develops SQZ Tolerizing Antigen Carriers.
How Does SQZB Make Money?
- Develops proprietary cell therapy platforms.
- Outlicenses or partners for commercialization.
- Generates revenue through research grants.
- Raises capital through equity offerings.
What Industry Does SQZB Operate In?
SQZ Biotechnologies Company operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory hurdles. The market for cell therapies is growing, driven by advancements in personalized medicine and immuno-oncology. Key trends include the development of allogeneic cell therapies, gene editing technologies, and combination therapies. SQZ Biotechnologies differentiates itself through its proprietary SQZ platform, which offers a unique approach to cell engineering. Competitors include companies focused on CAR-T cell therapy, gene therapy, and other immuno-oncology modalities. The success of SQZ Biotechnologies depends on its ability to demonstrate clinical efficacy and secure regulatory approvals in a rapidly evolving landscape.
Who Are SQZB's Key Customers?
- Patients with cancer.
- Patients with autoimmune diseases.
- Patients with infectious diseases.
- Pharmaceutical companies (potential partners).
- Research institutions (potential collaborators).
Company Profile
SQZ Biotechnologies Company operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Howard Bernstein. SQZB has traded publicly since 2020.
Financial Health
SQZ Biotechnologies Company's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -21.82 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for SQZ Biotechnologies Company stands at -87.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -74.1%, showing how much profit it generates from its asset base. A current ratio of 3.12 indicates the company holds enough short-term assets to cover its near-term obligations.
SQZB Valuation & Market Position
Relative to its peer group, SQZB's quantitative score of 47/100 is below the peer average of 70/100.
Earnings Track Record
SQZ Biotechnologies Company has missed Wall Street's EPS estimate in 4 of its last 7 reported quarters — a mixed record worth weighing.
Forward Outlook
Wall Street analysts project SQZ Biotechnologies Company revenue of about $40.0M for fiscal 2026, with EPS near $-4.39.
SQZB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in SQZ Biotechnologies' future prospects, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with growing discussions around the company's innovative approaches in the biotech sector.
- Recent advancements in their technology have generated excitement, positioning SQZ as a potential leader in its field.
- Increased media coverage and analyst interest highlight the company's unique value proposition, attracting attention from both retail and institutional investors.
Bear Case
- Despite recent positive sentiment, there remains skepticism regarding the scalability of their technology, with some questioning its long-term viability in the market.
- The biotech sector is notoriously volatile, and recent industry developments have raised concerns about regulatory hurdles that could impact SQZ's progress.
- Community discussions reveal a faction of investors worried about the company's financial health and its ability to sustain operations without further funding.
- Insider selling activity in the past has led to concerns about potential red flags, causing some investors to adopt a more cautious stance on the stock.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SQZB Latest News
No recent news available for SQZB.
SQZB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SQZB.
Price Targets
Wall Street price target analysis for SQZB.
SQZB MoonshotScore
What does this score mean?
The MoonshotScore rates SQZB 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Lawrence J. Knopf
CEO
Lawrence J. Knopf serves as the CEO of SQZ Biotechnologies Company. Information regarding his detailed career history, education, and previous roles is not available in the provided context. However, as CEO, he is responsible for leading the strategic direction and overall management of the company, guiding its efforts in developing cell therapies for various diseases.
Track Record: Information regarding Lawrence J. Knopf's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided context. His role involves overseeing the clinical development programs, securing funding, and building partnerships to advance the company's mission.
SQZB OTC Market Information
The OTC Other tier is the lowest tier of the OTC market, indicating that SQZ Biotechnologies Company may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading can be more speculative. These companies may be experiencing financial distress, be thinly traded, or have chosen not to comply with higher reporting standards, increasing the risk for investors compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of delisting or bankruptcy.
- Limited regulatory oversight.
- Verify the company's financial statements (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal issues.
- Monitor trading volume and price volatility.
- Company is incorporated and has a physical headquarters.
- The company has a website and publishes press releases.
- The company has a CEO and management team.
- The company is developing products and conducting clinical trials.
- The company was incorporated in 2013.
Common Questions About SQZB (Healthcare)
What does the AI Score mean for SQZB?
SQZB holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. SQZ Biotechnologies Company is a clinical-stage biotechnology firm specializing in cell therapies for cancer, autoimmune, and infectious diseases. Their lead candidate, SQZ-PBMC-HPV, is undergoing …
What does SQZ Biotechnologies Company do?
SQZ Biotechnologies Company is a clinical-stage biotechnology firm focused on developing cell therapies for cancer, autoimmune, and infectious diseases. They utilize their proprietary SQZ platform to engineer a patient's own cells to fight disease. Their lead product candidate, SQZ-PBMC-HPV, is in Phase I clinical trials targeting HPV16+ advanced or metastatic solid tumors. The company aims to create personalized cell therapies that address unmet medical needs.
What are the main risks for SQZB?
The main risks for SQZB include the potential failure of its clinical trials, which could significantly impact its valuation. Regulatory hurdles and competition from other biotechnology companies also pose challenges. As an OTC-listed company, SQZB faces additional risks related to liquidity, transparency, and regulatory oversight.
What are the key factors to evaluate for SQZB?
SQZ Biotechnologies Company (SQZB) holds an AI score of 47/100 (low). SQZ Biotechnologies Company presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology firms. Not financial advice.
How frequently does SQZB data refresh on this page?
SQZB's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SQZB's recent stock price performance?
SQZ Biotechnologies Company (SQZB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary SQZ platform technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SQZB overvalued or undervalued right now?
SQZ Biotechnologies Company (SQZB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SQZB before investing?
Before investing in SQZ Biotechnologies Company (SQZB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SQZB to a portfolio?
Key strength of SQZ Biotechnologies Company (SQZB): Proprietary SQZ platform technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.